Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus

11 de outubro de 2020 atualizado por: Janine Alessi, Federal University of Rio Grande do Sul

Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial

INTRODUCTION In critical situations, such as the current COVID 19 pandemic, themes of fear, uncertainty and stigmatization are common and constitute barriers to appropriate medical and mental health interventions. These challenges, when faced by those who live with a chronic disease, such as diabetes mellitus (DM), can negatively influence quality of life and adherence to treatment, compromising the control of the disease.

OBJECTIVES The present study aims to investigate the effectiveness of a tele-intervention during the COVID-19 pandemic in improving glycemic control, lipid profile, blood pressure levels and parameters of medication adherence, mental well-being and sleep quality in patients with type 1 DM and type 2 DM.

METHODS A randomized clinical trial will be carried out with patients with a previous diagnosis of type 1 DM and type 2 DM, who are registered at the Hospital de Clínicas de Porto Alegre (HCPA). Inclusion criteria will be age greater than or equal to 18 years, collection of HbA1c in the HCPA laboratory in January, February or March 2020 and availability to receive weekly phone calls. Patients will be randomized, stratified by type of diabetes, in two groups: G1: participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the social distancing period ; G2: participants will receive the usual care. The primary outcome assessed will be the variation in HbA1c levels comparatively between groups, with or without a tele-guided strategy, after four months of social distancing (or as long as the recommendation of social distancing measures remains). Secondary outcomes will include experiencing confirmation of COVID-19 infection, variation in lipid profile, blood pressure levels and variation in parameters of emotional distress related to diabetes, eating disorders, medication adherence, symptoms minor psychiatric disorders and altered sleep patterns, which will be evaluated with specific and validated scales. According to the sample calculation, 150 patients will be included in the study (92 with type 2 DM and 58 with type 1 DM). Analysis by intention to treat will be performed separately for patients with type 1 DM and with type 2 DM.

SCHEDULE The proposed experiment will start immediately after approval of this project by the research ethics committee. The duration of the proposed intervention is 4 months (or as long as the recommendation of social distancing measures remains. This means that the study may be completed before or after that period, based on national recommendations for social distancing in Brazil), with a data analysis plan and publication of the results until September 2020.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

149

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Rio Grande Do Sul
      • Porto Alegre, Rio Grande Do Sul, Brasil, 90620-170
        • Hospital de Clinicas de Porto Alegre

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Type 1 diabetes mellitus or type 2 diabetes mellitus;
  • Age greater than or equal to 18 years;
  • HbA1c assessed in January, February or March 2020;
  • Availability to receive weekly phone calls

Exclusion Criteria:

  • Any severe cognitive limitation that prevents the necessary interaction to carry out this study (advanced dementia, deafness, dysarthria, aphasia);
  • Do not present a telephone record in an electronic medical record;

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Tele-Intervention
Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
Sem intervenção: Usual Care
Participants will receive the usual care

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Variation in HbA1c levels
Prazo: 4 months (or as long as the recommendation of social distancing measures remains)
Variation in HbA1c levels comparatively between groups after the period of social distancing measures.
4 months (or as long as the recommendation of social distancing measures remains)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
COVID-19 infection
Prazo: 4 months (or as long as the recommendation of social distancing measures remains)
Confirmation of coronavirus infection by rapid test
4 months (or as long as the recommendation of social distancing measures remains)
Variation in lipid profile
Prazo: 4 months (or as long as the recommendation of social distancing measures remains)
Comparison of the lipid profile of the last year with the lipid profile after the intervention between the groups.
4 months (or as long as the recommendation of social distancing measures remains)
Variation in blood pressure levels
Prazo: 4 months (or as long as the recommendation of social distancing measures remains)
Comparison of the blood pressure level of the last consultation with the pressure after the intervention between the groups.
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of emotional distress associated with the routine of living with diabetes after intervention between groups
Prazo: 4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of emotional distress associated with the routine of living with diabetes - B-PAID (Brazilian Problem Areas In Diabetes Scale)
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of eating disorders between groups
Prazo: 4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of eating disorders - EAT - 26 SCALE (Teste de Atitudes Alimentares)
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of adherence to the proposed clinical treatment between groups
Prazo: 4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of adherence to the proposed clinical treatment - SCI R (Self-Care Inventory - revised)
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of minor psychiatric disorders between groups
Prazo: 4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of minor psychiatric disorders - SRQ 20 (Self Report Questionnaire)
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of sleep pattern changes between groups
Prazo: 4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of sleep pattern changes - MSQ (Mini Sleep Questionnaire)
4 months (or as long as the recommendation of social distancing measures remains)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

17 de abril de 2020

Conclusão Primária (Real)

20 de setembro de 2020

Conclusão do estudo (Real)

20 de setembro de 2020

Datas de inscrição no estudo

Enviado pela primeira vez

7 de abril de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de abril de 2020

Primeira postagem (Real)

14 de abril de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

14 de outubro de 2020

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de outubro de 2020

Última verificação

1 de outubro de 2020

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF
  • ANALYTIC_CODE
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

3
Se inscrever